Results 111 to 120 of about 4,208 (171)

Why Is C5a Inflammatory Complement Inhibition Not Enough to Improve C3 Glomerulopathy?

J Am Soc Nephrol
Zipfel PF, Skerka C.
europepmc   +1 more source

Comparative Analysis of Proteinuria and Longitudinal Outcomes in Immune Complex Membranoproliferative Glomerulonephritis and C3 Glomerulopathy. [PDF]

Kidney Int Rep
Caravaca-Fontán F, Toledo-Rojas R, Huerta A, Pérez-Canga JL, Martínez-Miguel P, Miquel R, Da Silva I, Verdalles Ú, Albornoz M, Durán López CM, Mon C, Fernández-Juárez G, Praga M, C3G study group from the Spanish Group for the Study of Glomerular Diseases.   +13 more
europepmc   +1 more source

Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice. [PDF]

Pediatr Transplant
Patry C, Webb NJA, Meier M, Pape L, Fichtner A, Höcker B, Tönshoff B.   +6 more
europepmc   +1 more source

Establishing the Future Direction of Clinical Outcomes in C3 Glomerulopathy: Perspectives From a Patient and a Physician. [PDF]

Kidney Med
Java A, Fuller L.
europepmc   +1 more source

Outcome of Patients Transplanted for C3 Glomerulopathy and Primary Immune Complex-Mediated Membranoproliferative Glomerulonephritis. [PDF]

Kidney Int Rep
Halfon M, Taffé P, Bucher C, Haidar F, Huynh-do U, Mani LY, Schachtner T, Wehmeier C, Venetz JP, Pascual M, Fakhouri F, Golshayan D, Swiss Transplant Cohort Study.   +12 more
europepmc   +1 more source

Anticomplement Therapies for C3 Glomerulopathy and Immune-Complex Membranoproliferative Glomerulonephritis Recurrence - A Dawn of New Hope. [PDF]

Kidney Int Rep
Emma F, John P.
europepmc   +1 more source

Apolipoprotein E in dense deposits: a parting of the ways in C3 glomerulopathy. [PDF]

Clin Kidney J
Tavares J, Caravaca-Fontán F, Praga M.
europepmc   +1 more source

Successfully treated C3 glomerulopathy in which protein and genetic analyses were useful for diagnosis. [PDF]

CEN Case Rep
Kanzaki M, Kurahashi M, Watanabe K, Nishikawa M, Fukuoka K, Shimada N, Mizuno M, Asano K.   +7 more
europepmc   +1 more source

Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.

Clin J Am Soc Nephrol
Nester C, Decker DA, Meier M, Aslam S, Bomback AS, Caravaca-Fontán F, Cook TH, Feldman DL, Fremeaux-Bacchi V, Gale DP, Gooch A, Johnson S, Licht C, Mathur M, Pickering MC, Praga M, Remuzzi G, Selvarajah V, Smith RJ, Tabriziani H, van de Kar N, Wang Y, Wong E, Mistry K, Lim M, Portillo C, Balogun S, Trachtman H, Thompson A.   +28 more
europepmc   +1 more source

Corrigendum to "The Role of von Willebrand Factor in the Pathogenesis of C3 Glomerulopathy" [<i>Kidney International Reports</i> Volume 10, Issue 6, June 2025, Pages 1929-1938]. [PDF]

Kidney Int Rep
Hua Z, Chen Y, Han S, Yu X, Tan Y, Yu F, Chen M, Zhao M.   +7 more
europepmc   +1 more source